Q-omics provides the consensus-scored ZNF814 profile across patient tissues and cancer cell-line models. ZNF814 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ZNF814 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, ZNF814 RNA expression shows 20,509 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRP, and UVM as cancer lineages where ZNF814 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF814 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF814 survival associations across molecular data types. ZNF814 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF814 RNA expression–survival associations across cancer types. High ZNF814 expression shows unfavorable associations in LGG, ACC and SKCM, but favorable associations in BLCA, BRCA and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ZNF814 RNA expression.
This table summarizes ZNF814 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF814. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF814 shows lower tumor expression in KIRP and THCA and higher tumor expression in STAD, LIHC, BRCA and CHOL. The KIRP box plot shows higher ZNF814 RNA expression in normal versus tumor tissue (log2 FC = −0.795, t-test p < 0.001).
This table shows molecular features associated with ZNF814 in patient tissues and cancer cell lines. In patient samples, ZNF814 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF814 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
